Background: Specific immunotherapy with allergen is the only causative treatment for IgE-mediated allergies such as stinging insect allergy or hay fever and works by the induction of blocking antibodies and regulatory T lymphocytes. Objective: Does a hypothetical obstruction of tumor surveillance presupposing the induction of regulatory T cells really justify detaining immunotherapy to oncologic patients as suggested by recent guidelines? Methods: We report 6 patients (4 female, 2 male) suffering or having suffered from stage 1 cancer (4 melanomas, 1 lung cancer, 1 breast cancer) and concomitant IgE-mediated allergy. Four of them had a history of severe anaphylactic reactions to the insect yellow jacket, the 5th suffered from allergic rhinoconjunctivitis to dust mites, and the 6th to grass/rye pollen. Results: Between 2004 and 2010, subcutaneous immunotherapy was safely performed in 5 patients without signs of tumor reactivation. The cancer in 2 of them was diagnosed immediately after specific immunotherapy had been initiated and in another 2 the active cancer phase had already finished years before; the 5th suffered from a relapse around the time of the initiation of immunotherapy. At the time of the writing of the manuscript, 4 of them had already concluded 3 years of treatment, another one almost 1 year. The melanoma in the 6th patient was diagnosed 5 months after reaching the maintenance dose. Immunotherapy with grass/rye pollen was aborted in this patient based on current guidelines. Conclusions: Specific immunotherapy was safely administered in patients suffering concomitantly from IgE-mediated allergy and lower stage cancer.

Keywords:
Allergy, Allergen vaccination, Cancer, Contraindication, Desensitization, Hymenoptera allergy, Melanoma, Rhinoconjunctivitis, Tumor, Yellow jacket
1.
Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA: Role of T regulatory cells in immune regulation of allergic diseases. Eur J Immunol 2010;40:1–9.
2.
Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707–713.
3.
Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C, Francis JN, et al: Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007;119:937–943.
4.
Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, et al: Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120:2723–2733.
5.
Kleine-Tebbe J, Bufe A, Ebner C, Eigenmann P, Friedrichs F, Fuchs T, et al: Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 2009;18:508–537.
6.
Ruëff F, Bergmann KC, Brockow K, Fuchs T, Grübl A, Jung K, et al: Hauttests zur Diagnostik von allergischen Soforttypreaktionen. Allergo J 2010;19:402–415.
7.
Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T: Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007;144:137–142.
8.
Mueller HL: Maintenance of protection in patients treated for stinging insect hypersensitivity: a booster injection program. Pediatrics 1977;59:773–777.
9.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al: Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003;83:803–819.
10.
Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435–453.
11.
Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest 2009;136:260–271.
12.
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al: Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010;46:270–283.
13.
Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, et al: Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergologie 2006;29:135–156.
14.
Cox L, Li JT, Nelson H, Lockey R: Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120:S25–S85.
15.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(suppl 86):8–160.
16.
Sublingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009;64:1–59.
17.
Fricker M, Helbling A, Schwartz L, Müller U: Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997;100:11–15.
18.
Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, et al: Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047–1054.
19.
Ruëff F, Wenderoth A, Przybilla B: Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027–1032.
20.
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al: AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008;63:1255–1266.
21.
Talbot-Smith A, Fritschi L, Divitini ML, Mallon DFJ, Knuiman MW: Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003;157:606–612.
22.
Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE: Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005;162:212–221.
23.
Schabath MB, Gorlova OY, Spitz MR: Reply: ‘Cancer mortalitiy among US men and women with asthma and hay fever’. Am J Epidemiol 2006;163:394–395.
24.
Castaing M, Youngson J, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, et al: Is the risk of lung cancer reduced among eczema patients? Am J Epidemiol 2005;162:542–547.
25.
Wang H, Rothenbacher D, Low M, Stegmaier C, Brenner H, Diepgen TL: Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum. Int J Cancer 2006;119:695–701.
26.
Bakos N, Schöll I, Szalai K, Kundi M, Untersmayr E, Jensen-Jarolim E: Risk assessment in elderly for sensitization to food and respiratory allergens. Immunol Lett 2006;107:15–21.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.